N,N-dimethyl-2-methylpentylamine | 16627-36-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N,N-dimethyl-2-methylpentylamine
• 英文别名: N,N,2-trimethylpentan-1-amine；1-Dimethylamino-2-methyl-pentan；dimethyl-(2-methyl-pentyl)-amine
• CAS: 16627-36-4
• 化学式: C₈H₁₉N
• 分子量: 129.246
• InChiKey: FYRHPVBMURAQJE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  (二甲氨基)丙酮 在 镍 氢气 作用下， 生成 N,N-dimethyl-2-methylpentylamine
  参考文献：
  名称：

  Tiollais,R. et al., Comptes Rendus des Seances de l'Academie des Sciences, Serie C: Sciences Chimiques, 1967, vol. 264, p. 1662 - 1664

  摘要：

  DOI：

文献信息

• Synthesis of β‐Chiral Amines by Dynamic Kinetic Resolution of α‐Branched Aldehydes Applying Imine Reductases
  作者：Philipp Matzel、Sebastian Wenske、Simon Merdivan、Sebastian Günther、Matthias Höhne

  DOI：10.1002/cctc.201900806

  日期：2019.9.5

  2‐phenylpropanal and a substituted 2‐methyl‐3‐phenylpropanal: the corresponding N‐methylated β‐chiral amines were obtained with >95 % conversion and 78 and 95 %ee. Other amines were formed with low to moderate enantiomeric excess. This exemplifies the potential of IREDs for the one‐step synthesis of secondary β‐chiral amines, but also the challenge to identify highly selective enzymes for a desired amine

  亚胺还原酶（IRED）可通过酮的还原胺化一步制备旋光性仲胺和叔胺。到目前为止，通过这种方法主要制备了α-手性胺。在这项研究中，我们探索了合成β-手性胺的可能性，β-手性胺在药物中也经常被发现是结构性基序，但由于以下原因，制备难度更大：（i）醛底物已经含有手性中心，需要进行消旋，以实现完全转化。（ii）由于中间体亚胺的立体中心有两个碳原子靠近亚胺氮，因此与α-手性胺合成相比，实现高对映选择性更具挑战性。为了调查概念证明，我们首先证实，与5种不同的胺底物结合使用时，不同的IRED能够转化多种α-支链醛。来自的IRED链霉菌是促进2-苯基丙醛和取代的2-甲基-3-苯基丙醛动力学动力学拆分的合适酶：获得了相应的N-甲基化的β-手性胺，转化率> 95％，ee分别为78和95％。形成的其他胺的对映体过量较低至中等。这证明了IRED在一步法合成仲β-手性胺中的潜力，但也为鉴定所需胺产物的高选择性酶带来了挑战。
• Chemical compound, method for the production thereof and its use in catalyst systems for producing polyolefins
  申请人：——

  公开号：US20030013913A1

  公开（公告）日：2003-01-16

  The invention relates to a chemical compound of formula (I), wherein M 1 represents an element selected from main groups II, III or IV of the periodic table of elements; x is equal to 1, 2, 3 or 4; y is equal to 2, 3 or 4, and; A represents a cation of main group V of the periodic table of elements; R 1 is the same or different and represents a branched or unbranched linear or cyclic C 1 -C 40 group that contains carbon; R 2 is the same or different and represents a branched or unbranched linear or cyclic C 1 -C 40 group that contains carbon; R 3 represents a branched or unbranched linear or cyclic C 1 -C 40 group that contains carbon, and; R 4 represents a hydrogen atom; whereby R 2 and R 3 are always different from one another.

  本发明涉及一种化学式（I）的化合物，其中M1代表元素，所选自元素周期表的主要II、III或IV族；x等于1、2、3或4；y等于2、3或4，并且A代表元素周期表的主要V族的阳离子；R1相同或不同，代表含有碳的支链或直链线性或环状C1-C40基团；R2相同或不同，代表含有碳的支链或直链线性或环状C1-C40基团；R3代表含有碳的支链或直链线性或环状C1-C40基团，且R4代表氢原子；其中R2和R3始终彼此不同。
• TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR
  申请人：NISSAN CHEMICAL INDUSTRIES, LTD.

  公开号：US20150065705A1

  公开（公告）日：2015-03-05

  There is provided a novel triazinone compound that has an excellent T-type voltage-dependent calcium channel inhibitory activity and is specifically useful for treatment of pain. A compound of Formula (I), a tautomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof: where each substituent is defined in detail in the description or claims, for example R 1 is H or C 1-6 alkoxy, etc., each of L 1 and L 2 is independently a single bond or NR 2 , etc., L 3 is C 1-6 alkylene, etc., A is C 6-14 aryl or 5 to 10-membered heteroaryl which is optionally substituted, etc., B is C 3-11 cycloalkylene, etc., D is C 6-14 aryl or 5 to 10-membered heteroaryl which is optionally substituted, etc.

  提供了一种新型三嗪酮化合物，具有出色的T型电压依赖性钙离子通道抑制活性，并且特别适用于治疗疼痛。化合物式(I)的化合物，其互变异构体，其药学上可接受的盐或其溶剂化物：其中每个取代基在说明或权利要求书中详细定义，例如R1为H或C1-6烷氧基等，每个L1和L2分别独立地为单键或NR2等，L3为C1-6烷基等，A为C6-14芳基或5至10成员杂环芳基，可选地取代等，B为C3-11环烷基等，D为C6-14芳基或5至10成员杂环芳基，可选地取代等。
• COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF
  申请人：Sunovion Pharmaceuticals Inc.

  公开号：US20140349992A1

  公开（公告）日：2014-11-27

  Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

  本文提供了化合物及其合成方法。这些化合物可用于治疗、预防和/或管理各种疾病，如神经疾病、神经退行性疾病、神经精神疾病、认知、学习或记忆障碍、胃肠道疾病、下尿路障碍和癌症等。本文提供的化合物在中枢神经系统或外周调节代谢性谷氨酸受体5 (mGluR5) 的活性。本文还提供了含有这些化合物的药物制剂及其使用方法。
• TETRAHYDROISOQUINOLINES CONTAINING SUBSTITUTED AZOLES AS FACTOR XIA INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160145263A1

  公开（公告）日：2016-05-26

  The present invention provides compounds of Formula (I), or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

  本发明提供了公式(I)的化合物，或其立体异构体，互变异构体或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性因子XIa抑制剂或FXIa和血浆卡利肯酶的双重抑制剂。本发明还涉及包含这些化合物的制药组合物以及使用它们治疗血栓栓塞和/或炎症性疾病的方法。